此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)

2026年11月18日 更新者:Insmed Incorporated

INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators

The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.

研究概览

地位

招聘中

研究类型

观察性的

注册 (估计的)

69

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Los Angeles、California、美国、90095
        • 尚未招聘
        • USA004
    • Maryland
      • Baltimore、Maryland、美国、21287-0005
        • 招聘中
        • USA002
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • USA001
    • Texas
      • Houston、Texas、美国、77030-3008
        • 招聘中
        • USA003
      • Nottingham、英国、NG7 2UH
        • 招聘中
        • GBR001

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 10年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.

描述

Inclusion Criteria for the AT Cohort:

  • Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
  • If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.

Inclusion Criteria for the Healthy Comparator Cohort:

  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.

Exclusion Criteria for the AT Cohort:

  • Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.

Exclusion Criteria for the Healthy Comparator Cohort:

  • Diagnosis of any form of AT.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
AT Cohort

Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.

Healthy Comparator Cohort

Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
大体时间:Baseline up to Month 24
Baseline up to Month 24
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
大体时间:Baseline up to Month 24
Baseline up to Month 24

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Height
大体时间:Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Weight
大体时间:Baseline up to Month 24
Baseline up to Month 24
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
大体时间:Up to Month 24
Up to Month 24
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
大体时间:Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Motor Activity Assessed by Wearable Device
大体时间:Baseline up to Month 24

A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity.

Baseline up to Month 24
Change From Baseline in Arm Function Assessed by Hevelius Test
大体时间:Baseline up to Month 24
Baseline up to Month 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Director、Insmed Incorporated

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月30日

初级完成 (估计的)

2029年5月30日

研究完成 (估计的)

2029年5月30日

研究注册日期

首次提交

2026年10月30日

首先提交符合 QC 标准的

2026年11月18日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月18日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅